NasdaqGM - Nasdaq Real Time Price USD

Atai Life Sciences N.V. (ATAI)

1.3800

0.0000

(0.00%)

As of 2:11:33 PM EDT. Market Open.

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a clinical site initiation, an FDA authorization and an analyst initiation. CLEARMIND INITIATES U.S. SITE FOR CMND-100 TRIAL: Clearmind Medicine (CMND) announced Thursday that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first-in-human clinical trial will investigate the safety, tolerability and

TipRanks 4 days ago

RVVTF

AGNPF

ATAI
0.00%
Psychedelic: Exclusive talk with biotech company Clearmind Medicine

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine (CMND), a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights: PSYCHEDELIC PHARMA: Clearmind is a clinical-stage biotech company that aims to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods

TipRanks 24 days ago

CMND

ATAI
0.00%
GHRS
-0.77%
Psychedelic: atai Life Sciences, NRx report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-t

TipRanks 25 days ago

CYBN
+1.04%
ATAI
0.00%
CMND
Atai Life Sciences Full Year 2024 Earnings: Misses Expectations

Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2024 Results Key Financial Results Net loss: US$149.3m (loss widened by...

Simply Wall St. 27 days ago

ATAI
0.00%
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipated in mid-25 - Com

GlobeNewswire 29 days ago

ATAI
0.00%
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement. ATAI DOSES FIRST PATIENT IN PHASE 2 VLS-01 TRIAL: atai Life Sciences (ATAI) announced Tuesday that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine applied to the buccal surface, in people suffering from tre

TipRanks last month

ATAI
0.00%
MNMD
-0.54%
CMND
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being developed as a rapid-acting, robust and durable antidepressant for people suffering from treatment-resistant depression, which affects approximately 100 million people globally - VLS-01 is designed to fit within the established two-hour interventional

GlobeNewswire last month

ATAI
0.00%
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

- The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with treatment-resistant depression - The open-label extension stage of the Phase 2b clinical trial continues to enroll patients to evaluate the safety and efficacy of a second dose of BPL-003 - As previously reported, the Phase 2a study of BPL-003 in patients with treatment-resistant depression showed rap

GlobeNewswire last month

ATAI
0.00%
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Atai Life Sciences N.V. (NASDAQ:ATAI) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics […]

Insider Monkey last month

ATAI
0.00%
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks last month

QNTM

ENVB

CYBN
+1.04%
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat o

GlobeNewswire last month

ATAI
0.00%
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public offering price of

GlobeNewswire last month

ATAI
0.00%
atai Life Sciences Announces Pricing of Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering wi

GlobeNewswire last month

ATAI
0.00%
atai Life Sciences Announces Proposed Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering wi

GlobeNewswire last month

ATAI
0.00%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Scotts Miracle-Gro will finally separate its cannabis arm, Hawthorne, into a stand-alone cannabis business High Tide narrowed losses in 2024 amid record revenue and expansion plans Key Takeaways; Psychedelic Sector Awakn announced advances in novel therapies for alcohol use disorder and PTSD atai reported promising results from BPL-003 study for alcohol […]

Market Exclusive 2 months ago

SMG

OPTHF

AWKNF
Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges

As the U.S. stock market navigates a week of fluctuating earnings reports and economic indicators, investors are keenly observing opportunities across various sectors. Penny stocks, often associated with smaller or newer companies, continue to intrigue those looking for potential growth at lower price points. Despite their vintage label, these stocks can offer significant value when backed by strong financials and fundamentals, presenting an appealing option for investors seeking overlooked...

Simply Wall St. 2 months ago

ATAI
0.00%
ZVIA

RLX
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months - BPL-003 was well-tolerated with no serious or severe adverse events reported NEW YORK and BERLIN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,

GlobeNewswire 2 months ago

ATAI
0.00%
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments t

GlobeNewswire 3 months ago

ATAI
0.00%
US Penny Stocks To Consider In December 2024

As the United States stock market navigates a period of volatility, with major indexes managing to hold onto gains despite recent fluctuations, investors are exploring diverse opportunities. Penny stocks, though often viewed as a throwback term, continue to offer potential for growth by representing smaller or newer companies at lower price points. When these stocks are backed by strong financials and solid fundamentals, they can provide an intriguing opportunity for investors seeking hidden...

Simply Wall St. 3 months ago

ATAI
0.00%
SMRT

INUV
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch

The U.S. stock market has recently shown signs of recovery, with the S&P 500 and Nasdaq Composite rebounding after a challenging week, highlighting the resilience of equities amid fluctuating investor sentiment. Penny stocks may be an older term, but they continue to offer intriguing investment opportunities by allowing investors to access potential growth in smaller or newer companies at lower price points. When these stocks are supported by strong financial health and solid fundamentals,...

Simply Wall St. 4 months ago

QD

OXBR

OXBRW

Performance Overview

Return	ATAI	S&P 500 (^GSPC)
YTD	+3.76%	-8.28%
1-Year	-33.33%	+6.58%
3-Year	-74.06%	+22.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Atai Life Sciences N.V. (ATAI)

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

Atai Life Sciences Full Year 2024 Earnings: Misses Expectations

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

US Penny Stocks To Consider In December 2024

Oxbridge Re Holdings Among 3 US Penny Stocks To Watch

Performance Overview